Insulin costs have been steadily increasing, forcing many people with diabetes to choose between purchasing this live-sustaining medication or paying for other necessities. In May 2018, the ADA’s Insulin Access and Affordability Working Group released findings from their research and stakeholder discussions. As follow-up to the Working Group’s work, the ADA has released a Public Policy Statement with an array of short-term and long-term recommendations to help shed additional light on the issue, to combat increasing insulin costs, and to improve affordable access to medications, including:

  • Streamlining the biosimilar approval process
  • Increasing pricing transparency throughout the insulin supply chain
  • Lowering or removing patient cost-sharing for insulin
  • Increasing access to health care coverage for all people with diabetes.
Copyright © American Diabetes Association 2018. All rights reserved.